Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Completed × sitravatinib × Clear all

Phase

Phase 1 5 Phase 1/2 2 Phase EARLY_PHASE1 1 Phase 3 1 Phase 2/3 1 Phase 2 1

Status

Withdrawn 1 Terminated 1 Enrolling by invitation 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Metastatic Non-Squamous Non-Small Cell Lung Cancer 1

Interventions

Cyclophosphamide 267 Cisplatin 254 Radiotherapy 230 Paclitaxel 222 Fluorouracil 204 Docetaxel 203 Carboplatin 199 Doxorubicin 198 Dexamethasone 151 Gemcitabine 138 Vincristine 131 Etoposide 119 Prednisone 116 Leucovorin 116 Capecitabine 116 Bevacizumab 109 Methotrexate 106 Rituximab 105 Cytarabine 99 Trastuzumab 86 Filgrastim 86 Oxaliplatin 82 pembrolizumab 68 Tamoxifen 62 Drug Therapy 62 Pemetrexed 61 Epirubicin 60 Irinotecan 57 Chemotherapy, Adjuvant 54 Granulocyte Colony-Stimulating Factor 52

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03906071 2025-10-21

SAPPHIRE

Mirati Therapeutics Inc.

Phase 3 Completed

577 enrolled 22 charts

Metastatic Non-Squamous Non-Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡